Skip to main content
Equibles
NSPR logo

NSPR · InspireMD, Inc.

Track NSPR — free

Use NSPR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NSPR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.98 +0.14 (+16.94%) At close · Aug 14
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$45.67M
Shares
46.49M

InspireMD, Inc. Earnings Call Transcripts

Every quarterly earnings call for InspireMD, Inc. (NSPR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲17.6% $1.18M −$4.48M '22 Q1 22-05-10 ▲47.5% $1.53M −$4.64M '22 Q2 22-08-11 ▲33.6% $1.43M −$4.53M '22 Q3 22-11-08 ▼25.7% $1.03M −$4.84M '22 Q4 23-03-30 ▲4.7% $1.24M −$4.26M '23 Q1 23-05-16 ▲7.7% $1.65M −$5.08M '23 Q2 23-08-08 ▲8.7% $1.56M −$5.18M '23 Q3 23-11-06 ▲71.6% $1.76M −$5.41M '23 Q4 24-03-06 ▲22% $1.51M −$7.03M '24 Q1 24-05-14 ▲5.5% $1.74M −$7.91M '24 Q2 24-08-06 ▲16.3% $1.81M −$7.89M '24 Q3 24-09-30 ▲10.7% $1.95M −$9.17M '24 Q4 25-03-12 ▲1.2% $1.53M −$11.17M '25 Q1 25-05-09 ▲2.2% $1.78M −$13.15M '25 Q2 25-08-05 ▲39.4% $2.52M −$12.71M '25 Q3 25-11-04 LATEST ▲122.2% $3.40M −$13.69M '26 Q1 26-05-04
Earnings call
FY26 · Q1
2026-05-04
InspireMD, Inc. Q4 FY2025 Earnings Call
Balanced tone Voluntary U.S. pause of Seaguard Prime 135 delivery system TCAR strategy with Seaguard Prime 80 International (OUS) revenue growth
Revenue
$3.40M
▲ 122.2% YoY
Diluted EPS
$-0.16
▼ 172.7% YoY
Gross margin
20.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-11-04
InspireMD, Inc. Q3 FY2025 Earnings Call
Confident tone U.S. Launch of CGuard Prime International Business Clinical Trial Pipeline
Revenue
$2.52M
▲ 39.4% YoY
Diluted EPS
$-0.17
Gross margin
34.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
InspireMD, Inc. Q2 FY2025 Earnings Call
Confident tone C-GUARDIANS II pivotal TCAR study FDA approval and U.S. commercial launch of CGuard Prime Stent-first carotid intervention market opportunity
Revenue
$1.78M
▲ 2.2% YoY
Diluted EPS
$-0.26
Gross margin
17.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
InspireMD, Inc. Q1 FY2025 Earnings Call
Confident tone CGuard Prime U.S. FDA Approval FDA Timeline and Regulatory Uncertainty Market Opportunity and Procedural Shift
Revenue
$1.53M
▲ 1.2% YoY
Diluted EPS
$0.22
Gross margin
19.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
InspireMD, Inc. Q4 FY2024 Earnings Call
Confident tone CGuard Prime US Launch TCAR Market Opportunity Clinical Pipeline and Studies
Revenue
$1.95M*
▲ 10.7% YoY
Gross margin
24.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
InspireMD, Inc. Q3 FY2024 Earnings Call
Confident tone U.S. CGuard Prime Approval & Launch TCAR Pipeline (SwitchGuard / CGuardians II) U.S. Launch Targeting Strategy
Revenue
$1.81M
▲ 16.3% YoY
Diluted EPS
$-0.16
Gross margin
22.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
InspireMD, Inc. Q2 FY2024 Earnings Call
Confident tone C-GUARDIANS pivotal trial data and PMA submission SwitchGuard TCAR platform and pipeline CREST-2 clinical trial completion
Revenue
$1.74M
▲ 5.5% YoY
Diluted EPS
$-0.22
Gross margin
19.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
InspireMD, Inc. Q1 FY2024 Earnings Call
Confident tone SwitchGuard / TCAR Development C-Guardians Pivotal Trial and U.S. PMA CGuard Revenue Growth
Revenue
$1.51M
▲ 22% YoY
Diluted EPS
$-0.21
Gross margin
19.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
InspireMD, Inc. Q4 FY2023 Earnings Call
Confident tone CGuard carotid stent platform and commercial growth C-Guardians U.S. pivotal trial and PMA timeline SwitchGuard / C-Guardians II and TCAR toolset
Revenue
$1.76M*
▲ 71.6% YoY
Gross margin
28.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
InspireMD, Inc. Q3 FY2023 Earnings Call
Revenue
$1.56M
▲ 8.7% YoY
Diluted EPS
$-0.15
Gross margin
28.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
InspireMD, Inc. Q2 FY2023 Earnings Call
Revenue
$1.65M
▲ 7.7% YoY
Diluted EPS
$-0.24
Gross margin
29.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-16
InspireMD, Inc. Q1 FY2023 Earnings Call
Revenue
$1.24M
▲ 4.7% YoY
Diluted EPS
$-0.53
Gross margin
30.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
InspireMD, Inc. Q4 FY2022 Earnings Call
Revenue
$1.03M*
▼ 25.7% YoY
Gross margin
19.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
InspireMD, Inc. Q3 FY2022 Earnings Call
Revenue
$1.43M
▲ 33.6% YoY
Diluted EPS
$-0.58
Gross margin
25.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
InspireMD, Inc. Q2 FY2022 Earnings Call
Revenue
$1.53M
▲ 47.5% YoY
Diluted EPS
$-0.59
Gross margin
28.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
InspireMD, Inc. Q1 FY2022 Earnings Call
Revenue
$1.18M
▲ 17.6% YoY
Gross margin
10.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
InspireMD, Inc. Q4 FY2021 Earnings Call
Revenue
$1.38M*
▲ 773.4% YoY
Gross margin
21.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
InspireMD, Inc. Q3 FY2021 Earnings Call
Revenue
$1.07M
▲ 9.3% YoY
Gross margin
8.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
InspireMD, Inc. Q2 FY2021 Earnings Call
Revenue
$1.04M
▲ 231.6% YoY
Gross margin
25.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
InspireMD, Inc. Q1 FY2021 Earnings Call
Revenue
$1.01M
▼ 2.7% YoY
Gross margin
10.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
InspireMD, Inc. Q4 FY2020 Earnings Call
Revenue
$158,000*
▼ 84.4% YoY
Gross margin
-246.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
InspireMD, Inc. Q3 FY2020 Earnings Call
Revenue
$980,000
▲ 4.4% YoY
Gross margin
30.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
InspireMD, Inc. Q2 FY2020 Earnings Call
Revenue
$313,000
▼ 76.9% YoY
Gross margin
-38.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
InspireMD, Inc. Q1 FY2020 Earnings Call
Revenue
$1.03M
▲ 149.2% YoY
Gross margin
28.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1433607 CUSIP 45779A846 13F (30d) 35 filings 35 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)